Literature DB >> 21356247

Nuclear factor-kappa B mediates TRPV4-NO pathway involved in thermal hyperalgesia following chronic compression of the dorsal root ganglion in rats.

Chao Wang1, Li-Ping Ning, Yong-Hui Wang, Yang Zhang, Xin-Li Ding, Hong-You Ge, Lars Arendt-Nielsen, Shou-Wei Yue.   

Abstract

The aim of this study was to test the hypothesis that nuclear factor-kappa B (NF-κB) is involved in TRPV4-NO pathway in thermal hyperalgesia following chronic compression of the dorsal root ganglion (DRG) (the procedure hereafter termed CCD) in rat. Intrathecal administration of two NF-κB inhibitors, pyrrolidine dithiocarbamate (PDTC; 10(-1) to 10(-2)M) and BAY (100-50 μM), both induced significantly dose-dependent increase in the paw withdrawal latency (PWL) and decrease in nitric oxide (NO) content in DRG when compared with control rats. Pretreatment with 4α-phorbol 12,13-didecanoate (4α-PDD, transient receptor potential vanilloid 4 (TRPV4) synthetic activator, 1 nm) attenuated the suppressive effects of PDTC (10(-1)M) and BAY (100 μM) on CCD-induced thermal hyperalgesia and NO production. In addition, Western blot analysis indicated that CCD rats exhibited nuclear NF-κB protein expression and low levels of cytoplasmic inhibitory-kappa B (I-κB) expression; the increase in NF-κB expression and decrease in I-κB expression were reversed after intrathecal injection of PDTC. In conclusion, our data suggested that NF-κB could be involved in TRPV4-NO pathway in CCD-induced thermal hyperalgesia.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356247     DOI: 10.1016/j.bbr.2011.02.028

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

1.  Observing Anti-inflammatory and Anti-nociceptive Activities of Glycyrrhizin Through Regulating COX-2 and Pro-inflammatory Cytokines Expressions in Mice.

Authors:  Hong-Ling Wang; Yu-Xiang Li; Ya-Ting Niu; Jie Zheng; Jing Wu; Guang-Jiang Shi; Lin Ma; Yang Niu; Tao Sun; Jian-Qiang Yu
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 2.  Regulation of Pain and Itch by TRP Channels.

Authors:  Carlene Moore; Rupali Gupta; Sven-Eric Jordt; Yong Chen; Wolfgang B Liedtke
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

3.  N-Pyrazoloyl and N-thiopheneacetyl hydrazone of isatin exhibited potent anti-inflammatory and anti-nociceptive properties through suppression of NF-κB, MAPK and oxidative stress signaling in animal models of inflammation.

Authors:  Sara Zeeshan; Muhammad Naveed; Adnan Khan; Ayesha Atiq; Maryam Arif; Muhammad Naeem Ahmed; Yeong Shik Kim; Salman Khan
Journal:  Inflamm Res       Date:  2019-05-11       Impact factor: 4.575

Review 4.  The Role of Saponins in the Treatment of Neuropathic Pain.

Authors:  Bei Tan; Xueqing Wu; Jie Yu; Zhong Chen
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

5.  Mineralocorticoid Receptor, A Promising Target for Improving Management of Low Back Pain by Epidural Steroid Injections.

Authors:  Shaimaa I A Ibrahim; Judith A Strong; Jun-Ming Zhang
Journal:  J Anesth Perioper Med       Date:  2016-07-26

6.  Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats.

Authors:  Zi Wang; Haizhen Huang; Shaozhong Yang; Shanshan Huang; Jingxuan Guo; Qi Tang; Feng Qi
Journal:  Int J Nanomedicine       Date:  2016-05-17

7.  Enhanced binding capability of nuclear factor-κB with demethylated P2X3 receptor gene contributes to cancer pain in rats.

Authors:  You-Lang Zhou; Guo-Qin Jiang; Jinrong Wei; Hong-Hong Zhang; Wei Chen; Hongyan Zhu; Shufen Hu; Xinghong Jiang; Guang-Yin Xu
Journal:  Pain       Date:  2015-10       Impact factor: 7.926

8.  Effect of TRPV4-p38 MAPK Pathway on Neuropathic Pain in Rats with Chronic Compression of the Dorsal Root Ganglion.

Authors:  Yu-Juan Qu; Xiao Zhang; Zhen-Zhen Fan; Juan Huai; Yong-Bo Teng; Yang Zhang; Shou-Wei Yue
Journal:  Biomed Res Int       Date:  2016-06-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.